TEST:

Prolaris®

📢 ASCO 2023 Prostate Cancer 🙌🎉 ➡️ Can you explain the #CCR score and how it combines different assessment tools to evaluate prostate cancer aggressiveness? @prostatemd @UofUHealth #Prolaris #ProstateCancer #ASCO23 🔗 https://t.co/jg2TGeT5Ui (@oncologytube)

After talking two AS candidate pts in one clinic back from the cliff edge, I’m really feeling the need to yell into the void just how much I loathe the new @ProlarisTest score report 🤢🤦‍♂️#pcsm @myriadgenetics (@dr_coops)

We are pleased to announce that our research on the clinical utility of the Prolaris® test in intermediate risk patients with #ProstateCancer was presented by @prostatemd at #WSAUA22. If you missed the presentation, more information can be found here: https://t.co/jBwsoAQAB2 ()

We are pleased to share our podium presentation at #WSAUA22 on the utility of the Prolaris® test in intermediate risk patients with #prostatecancer. @ProstateMD will present on Nov. 4 at 8:45 a.m. HST, #147. For those not in attendance, read more at: https://t.co/jBwsoAQAB2 (@myriadgenetics)

Great talk by Alicia Morgans @CaPsurvivorship at #SUO21 regarding the importance of germline AND somatic genetic testing in ALL men with mCRPC!! Drop by the Myriad Genetics Booth if you have any questions. @MyriadMyRisk #BRACAnalysisCDx @ProlarisTest (@RobFinchCGC)

Precision medicine for #prostatecancer helps us escalate or deescalate therapy accordingly #radonc @myriadgenetics @ProlarisTest https://t.co/4n4GkpK9pF (@KerwinXRT)

Video: Dr. Jonathan Tward discusses his experience with the Prolaris test for prostate cancer https://t.co/d2rQflndOG #urology #urologist #prostatecancer @huntsmancancer @prostatemd (@UrologyTimes)

Day1⃣ #GU21 #OncoAlertTopTweet 🚨by @neerajaiims Prolaris test may allow some pts with localized @prostatecancer avoid androgen deprivation Rx. (@OncoAlert)

#GU21 @ASCO Very proud to see my dear friend Dr. Jonathan Tward @prostatemd @huntsmancancer @Huntsman_GU giving this excellent talk 👉Prolaris test may allow some pts with localized @prostatecancer avoid androgen deprivation Rx. Must watch @DrPaulNguyen @OncoAlert @PCF_Science (@neerajaiims)

"Urologist poll: Are you using tissue markers (eg Decipher, Oncotype, Prolaris) in newly diagnosed favorable-risk #prostatecancer patients to help guide management decisions? #nsaua19" (@LoebStacy)